Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases: A case report

Oncology Letters

Volumn 6, Issue 2, 2013, Pages 448-452

  He, Shizhi ^a   Li, Pingdong ^a   Chen, Xiaohong ^a   Yu, Zhenkun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Circulating tumor cells; Head and neck cancer; Ovarian cancer; Supraclavicular lymph node metastases; Unknown primary tumor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; THYROID TRANSCRIPTION FACTOR 1;

ADENOCARCINOMA; ADULT; BIOPSY; CASE REPORT; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUID BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW; SALPINGOOOPHORECTOMY;

EID: 84879479711     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1364     Document Type: Review

References (30)

1. Strojan P, Ferlito A, Medina JE, etal: Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck35: 123-132, 2011.
2. Gervasoni A, Sandri MT, Nascimbeni R, etal: Comparison of three distinct methods for the detection of circulating tumor cells in colorectal cancer patients. Oncol Rep25: 1669-1703, 2011.
3. Strojan P, Ferlito A, Langendijk JA, etal: Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck35: 286-293, 2013.
4. Haas I, Hoffmann TK, Engers R and Ganzer U: Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol259: 325-333, 2002.
5. Giridharan W, Hughes J, Fenton JE and Jones AS: Lymph node metastases in the lower neck. Clin Otolaryngol Allied Sci28: 221-226, 2003.
6. Chepeha D, Koch W and Pitman K: Management of unknown primary tumor. Head Neck25: 499-504, 2003.
7. Cerezo L, Raboso E and Ballesteros AI: Unknown primary cancer of the head and neck: a multidisciplinary approach. Clin Transl Oncol13: 88-97, 2011.
8. Oien KA: Pathologic evaluation of unknown primary cancer. Semin Oncol36: 8-37, 2009.
9. van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW and denToonder JM: Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res71: 5955-5960, 2011.
10. Pantel K, Brakenhoff RH and Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer8: 329-340, 2008.
11. Smirnov DA, Foulk BW, Doyle GV, Connelly MC, TerstappenLW and O'Hara SM: Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Research66: 2918-2922, 2006.
12. Marrinucci D, Bethel K, Bruce RH, etal: Case study of the morphologic variation of circulating tumor cells. Human Pathol38: 514-519, 2007.
13. Bellone S, Siegel ER, Cocco E, etal: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer19: 860-866, 2009.
14. Shim HS, Yoon BS and Cho NH: Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Human Pathol40: 693-698, 2009.
15. Miller MC, Doyle GV and Terstappen LW: Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. JOncol2010: 617421, 2010.
16. Poveda A, Kaye SB, McCormack R, etal: Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol122: 567-572, 2011.
17. Rusthoven KE, Koshy M and Paulino AC: The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer101: 2641-2649, 2004.
18. Kwee TC and Kwee RM: Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol19: 731-744, 2009.
19. Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K and Schwaiger M: Clinical applications of FDG PET and PET/CT in head and neck cancer. JOncol2009: 208725, 2009.
20. Fanti S, Nanni C, Castellucci P, etal: Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding. Cancer Imaging6: 20-23, 2006.
21. Dvoretsky PM, Richards KA, Angel C, etal: Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol19: 57-63, 1988.
22. Euscher ED, Silva EG, Deavers MT, Elishaev E, GershensonDM and Malpica A: Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol28: 1217-1223, 2004.
23. Moll R, Löwe A, Laufer J and Franke WW: Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol140: 427-447, 1992.
24. Rubin BP, Skarin AT, Pisick E, Rizk M and Salgia R: Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev 10: 77-82, 2001.
25. Roh MS and Hong SH: Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. J Korean Med Sci17: 512-517, 2002.
26. Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P and DietelM: Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 29: 233-240, 1996.
27. Mittal K, Soslow R and McCluggage WG: Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med132: 402-423, 2008.
28. Acs G, Pasha T and Zhang PJ: WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol23: 110-118, 2004.
29. Malpica A, Deavers MT, Gershenson D, Tortolero-Luna G and SilvaEG: Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential. Am J Surg Pathol25: 988-996, 2001.
30. Verbruggen MB, Verheijen RH, van de Goot FR, vanBeurdenM, Dorsman JC and van Diest PJ: Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases. Am J Surg Pathol30: 739-743, 2006.